Gemcitabine and lenalidomide combination in a patient with metastatic pancreatic cancer: a case study

被引：0
作者：
Wai M. Liu
Shiyam Nizar
Angus G. Dalgleish
机构：
[1] St. George’s University of London,Department of Oncology, Division of Cellular and Molecular Medicine
来源：
Medical Oncology | 2010年 / 27卷
关键词：
Pancreatic cancer; Drug combination therapy; Gemcitabine; Lenalidomide;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The proportion of people surviving pancreatic cancer is extremely low, with just 10% of patients diagnosed with any stage of the disease living beyond 1 year and a 5-year relative survival rate of <5%. The lack of effective therapy is one the main reason for such a bleak outlook. Herein, we report on a patient with pancreatic adenocarcinoma and metastatic disease treated with a combination regimen of gemcitabine and lenalidomide, without major complications. We also present in vitro data that highlight a hyper-additive effect of the two drugs when used in combination. To date, 33 months after diagnosis, the patient remains well and continues in full-time employment.
引用
收藏
页码：430 / 433
页数：3
相关论文
共 68 条
  • [1] Jemal A(2008)Cancer statistics, 2008 CA Cancer J Clin 58 71-96
  • [2] Siegel R(2008)Analysis of mortality rates for pancreatic cancer across the world HPB (Oxford) 10 58-62
  • [3] Ward E(2009)Recent advances and developments in treatment strategies against pancreatic cancer Curr Clin Pharmacol 4 102-12
  • [4] Hao Y(1997)Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 2403-2413
  • [5] Xu J(2004)Pancreatic cancer Lancet 363 1049-1057
  • [6] Murray T(2004)Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers Br J Cancer 90 955-961
  • [7] Thun MJ(2008)Enhancing the cytotoxic activity of novel targeted therapies—is there a role for a combinatorial approach? Curr Clin Pharmacol 3 108-117
  • [8] Hariharan D(2000)Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells Blood 96 3838-3846
  • [9] Saied A(2004)Derangement of immune responses by myeloid suppressor cells Cancer Immunol Immunother 53 64-72
  • [10] Kocher HM(2005)Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity Clin Cancer Res 11 6713-6721
1234567